Myelodysplastic syndromes and overlap syndromes

다국어 초록 (Multilingual Abstract)

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological neoplasms characterized by ineffective hematopoiesis, morphologic dysplasia, and cytopenia. MDS overlap syndromes include various disorders, such as myelodysplastic/ myeloproliferative neoplasms and hypoplastic MDS with aplastic anemia characteristics. MDS overlap syndromes share the characteristics of other diseases, which make differential diagnoses challenging. Advances in genomic studies have led to the discovery of frequent mutations in MDS and overlap syndromes; however, most of the mutations are not specific for the diagnosis of these diseases. The molecular characteristics of the overlap syndromes usually do not show a just “in-between” form but rather heterogeneous features. Established diagnostic criteria for these diseases based on clinical, morphologic, and laboratory features are still useful when combined with genomic data. It is expected that further studies for MDS and overlap syndromes will place emphasis on the roles of mutations as therapeutic targets and prognostic indicators.

참고문헌 (Reference)

1 Yoshimi A, "Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia" 60 : 836-841, 2013

2 Patnaik MM, "WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88consecutive patients : survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations" 24 : 1283-1289, 2010

3 Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues" IARC 2017

4 Manabe A, "Viral infections in juvenile myelomonocytic leukemia : prevalence and clinical implications" 26 : 636-641, 2004

5 Arber DA, "Update on the pathologic diagnosis of chronic myelomonocytic leukemia" 32 : 732-740, 2019

6 Strauss A, "Unmistakable morphology? Infantile malignant osteopetrosis resembling juvenile myelomonocytic leukemia in infants" 167 : 486-488, 2015

7 Jerez A, "Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited" 30 : 1343-1349, 2012

8 Malcovati L, "Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes" 25 : 3503-3510, 2007

9 Patnaik MM, "Therapy related-chronic myelomonocytic leukemia(CMML) : molecular, cytogenetic, and clinical distinctions from de novo CMML" 93 : 65-73, 2018

10 Carulli G, "The syndrome of abnormal chromatin clumping in leukocytes" 82 : 635-636, 1997

11 Invernizzi R, "The syndrome of abnormal chromatin clumping in leucocytes : clinical and biological study of a case" 75 : 532-536, 1990

12 Meggendorfer M, "The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms" 103 : e192-e195, 2018

13 Stieglitz E, "The genomic landscape of juvenile myelomonocytic leukemia" 47 : 1326-1333, 2015

14 Vardiman JW, "The World Health Organization(WHO)classification of the myeloid neoplasms" 100 : 2292-2302, 2002

15 Ingram W, "The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow" 20 : 1319-1321, 2006

16 Arber DA, "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia" 127 : 2391-2405, 2016

17 Vardiman JW, "The 2008 revision of the World Health Organization(WHO)classification of myeloid neoplasms and acute leukemia : rationale and important changes" 114 : 937-951, 2009

18 Patnaik MM, "Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia" 92 : 542-548, 2017

19 Kulasekararaj AG, "TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis" 160 : 660-672, 2013

20 Jädersten M, "TP53 mutations in low-risk myelodysplastic syndromes with del(5q)predict disease progression" 29 : 1971-1979, 2011

21 Germing U, "Survival, prognostic factors and rates of leukemic transformation in 381untreated patients with MDS and del(5q) : a multicenter study" 26 : 1286-1292, 2012

22 Szpurka H, "Spectrum of mutations in RARS-T patients includes TET2 and ASXL1mutations" 34 : 969-973, 2010

23 Sugimoto Y, "Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations" 150 : 83-87, 2010

24 Meggendorfer M, "Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia" 99 : e244-6, 2014

25 Bejar R, "Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation" 32 : 2691-2698, 2014

26 Tartaglia M, "Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia" 34 : 148-150, 2003

27 Papaemmanuil E, "Somatic SF3B1mutation in myelodysplasia with ring sideroblasts" 365 : 1384-1395, 2011

28 Sato-Otsubo A, "Single-nucleotide polymorphism array karyotyping in clinical practice : where, when, and how" 39 : 13-25, 2012

29 Malcovati L, "SF3B1-mutant MDS as a distinct disease subtype : a proposal from the International Working Group for the Prognosis of MDS" 136 : 157-170, 2020

30 Malcovati L, "SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts" 126 : 233-241, 2015

31 Meggendorfer M, "SETBP1mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations" 27 : 1852-1860, 2013

32 Wong TN, "Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia" 518 : 552-555, 2015

33 Patnaik MM, "Refractory anemia with ring sideroblasts(RARS)and RARS with thrombocytosis(RARS-T) : 2017 update on diagnosis, risk-stratification, and management" 92 : 297-310, 2017

34 Jeromin S, "Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations" 100 : e125-e127, 2015

35 Schuler E, "Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias" 38 : 1413-1419, 2014

36 Graubert TA, "Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes" 44 : 53-57, 2011

37 Piazza R, "Recurrent SETBP1mutations in atypical chronic myeloid leukemia" 45 : 18-24, 2013

38 Gambacorti-Passerini CB, "Recurrent ETNK1 mutations in atypical chronic myeloid leukemia" 125 : 499-503, 2015

39 Arber DA, "Reclassifying myelodysplastic syndromes : what’s where in the new WHO and why" 2015 : 294-298, 2015

40 Loh ML, "Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia" 152 : 677-687, 2011

41 Kuo MC, "RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation" 23 : 1426-1431, 2009

42 Ricci C, "RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant" 16 : 2246-2256, 2010

43 Valent P, "Proposed diagnostic criteria for classical chronic myelomonocytic leukemia(CMML), CMML variants and pre-CMML conditions" 104 : 1935-1949, 2019

44 Itzykson R, "Prognostic score including gene mutations in chronic myelomonocytic leukemia" 31 : 2428-2436, 2013

45 Patnaik MM, "Prognostic irrelevance of ring sideroblast percentage in World Health Organizationdefined myelodysplastic syndromes without excess blasts" 119 : 5674-5677, 2012

46 Tiu RV, "Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies" 117 : 4552-4560, 2011

47 Onida F, "Prognostic factors and scoring systems in chronic myelomonocytic leukemia : a retrospective analysis of 213 patients" 99 : 840-849, 2002

48 Malcovati L, "Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria : a basis for clinical decision making" 23 : 7594-7603, 2005

49 Patnaik MM, "Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis(RARS-T)and the role of next-generation sequencing" 91 : 492-498, 2016

50 Maxson JE, "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML" 368 : 1781-1790, 2013

51 Geyer JT, "Oligomonocytic chronic myelomonocytic leukemia(chronic myelomonocytic leukemia without absolute monocytosis)displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia" 30 : 1213-1222, 2017

52 Skibenes ST, "Next-generation sequencing in hypoplastic bone marrow failure : what difference does it make" 106 : 3-13, 2021

53 Haase D, "New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes : evidence from a core dataset of 2124 patients" 110 : 4385-4395, 2007

54 Sangiorgio VFI, "Myeloid neoplasms with isolated del(5q)and JAK2 V617F mutation : a"grey zone"combination of myelodysplastic and myeloproliferative features" 105 : e276-e279, 2020

55 DiNardo CD, "Myelodysplastic/myeloproliferative neoplasms, unclassifiable(MDS/MPN, U) : natural history and clinical outcome by treatment strategy" 28 : 958-961, 2014

56 Sangiorgio VFI, "Myelodysplastic/myeloproliferative neoplasms : are morphology and immunophenotyping still relevant" 33 : 101139-, 2020

57 Hasserjian RP, "Myelodysplastic syndrome updated" 86 : 7-13, 2019

58 Musto P, "Myelodysplastic disorders carrying both isolated del(5q)and JAK2(V617F)mutation : concise review, with focus on lenalidomide therapy" 7 : 1043-1050, 2014

59 Voglová J, "Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease" 25 : 493-499, 2001

60 Thota S, "Myelodysplastic and myeloproliferative neoplasms : updates on the overlap syndromes" 59 : 803-812, 2018

61 Muramatsu H, "Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia" 115 : 1969-1975, 2010

62 Bresolin S, "Mutations of SETBP1and JAK3 in juvenile myelomonocytic leukemia : a report from the Italian AIEOP study group" 7 : 28914-28919, 2016

63 Makishima H, "Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis" 119 : 3203-3210, 2012

64 Damm F, "Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes" 119 : 3211-3218, 2012

65 Bose P, "Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable" 132 : 2100-2103, 2018

66 Goasguen JE, "Morphological evaluation of monocytes and their precursors" 94 : 994-997, 2009

67 Hunter AM, "Molecular genetics of MDS/MPN overlap syndromes" 33 : 101195-, 2020

68 Wassie EA, "Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia : a Mayo Clinic-French consortium study" 89 : 1111-1115, 2014

69 Malcovati L, "Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis" 114 : 3538-3545, 2009

70 Meggendorfer M, "Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact : a study on 123patients and 27 genes" 102 : 1502-1510, 2017

71 Tanaka TN, "MDS overlap disorders and diagnostic boundaries" 133 : 1086-1095, 2019

72 Haferlach T, "Landscape of genetic lesions in 944 patients with myelodysplastic syndromes" 28 : 241-247, 2014

73 Niemeyer CM, "Juvenile myelomonocytic leukemia:who’s the driver at the wheel?" 133 : 1060-1070, 2019

74 Lasho T, "Juvenile myelomonocytic leukemia-a bona fide RASopathy syndrome" 33 : 101171-, 2020

75 Caye A, "Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network" 47 : 1334-1340, 2015

76 Srour SA, "Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12" 174 : 382-396, 2016

77 Mallo M, "Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q" 25 : 110-120, 2011

78 Fattizzo B, "Hypoplastic myelodysplastic syndromes: just an overlap syndrome?" 13 : 132-, 2021

79 Sloand EM, "Hypocellular myelodysplasia" 23 : 347-360, 2009

80 Locatelli F, "How I treat juvenile myelomonocytic leukemia" 125 : 1083-1090, 2015

81 Gotlib J, "How I treat atypical chronic myeloid leukemia" 129 : 838-845, 2017

82 Jeromin S, "High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms" 98 : e15-e17, 2013

83 Niemeyer CM, "Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia" 42 : 794-800, 2010

84 Ogawa S, "Genetics of MDS" 133 : 1049-1059, 2019

85 Vainchenker W, "Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms" 129 : 667-679, 2017

86 Yoshizato T, "Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia : impact on outcome of stem cell transplantation" 129 : 2347-2358, 2017

87 Cervera N, "Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia" 89 : 604-609, 2014

88 Shiozawa Y, "Gene expression and risk of leukemic transformation in myelodysplasia" 130 : 2642-2653, 2017

89 Thol F, "Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes" 119 : 3578-3584, 2012

90 Choi JW, "F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia" 75 : 257-260, 2002

91 Sakaguchi H, "Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia" 45 : 937-941, 2013

92 Lavallée VP, "EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations" 125 : 140-143, 2015

93 Van den Berghe H, "Distinct haematological disorder with deletion of long arm of no. 5 chromosome" 251 : 437-438, 1974

94 Gina Zini, "Diagnostics and Prognostication of Myelodysplastic Syndromes" 대한진단검사의학회 37 (37): 465-474, 2017

95 Sakashita K, "Diagnosis and treatment of juvenile myelomonocytic leukemia" 58 : 681-690, 2016

96 Such E, "Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia" 121 : 3005-3015, 2013

97 Loghavi S, "Defining the boundary between myelodysplastic syndromes and myeloproliferative neoplasms" 12 : 651-669, 2019

98 Haase D, "Cytogenetic features in myelodysplastic syndromes" 87 : 515-526, 2008

99 Le Beau MM, "Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases" 88 : 1930-1935, 1996

100 Patnaik MM, "Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia" 6 : e393-, 2016

101 Faisal M, "Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia" 8 : 742-750, 2019

102 Itzykson R, "Clonal architecture of chronic myelomonocytic leukemias" 121 : 2186-2198, 2013

103 Mangaonkar AA, "Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable(MDS/MPN-U) : Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients" 34 : 656-661, 2020

104 Coltro G, "Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia(CMML)-a study of 1084 patients" 34 : 1407-1421, 2020

105 Bono E, "Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome" 33 : 2495-2505, 2019

106 Hernández JM, "Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia" 11 : 441-444, 2000

107 Malcovati L, "Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms" 118 : 6239-6246, 2011

108 Cannella L, "Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified(MDS/MPD-U)by WHO classification" 32 : 514-516, 2008

109 Papaemmanuil E, "Clinical and biological implications of driver mutations in myelodysplastic syndromes" 122 : 3616-3627, 2013

110 Loghavi S, "Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor : expanding the spectrum of skin lesions in chronic myelomonocytic leukemia" 44 : 1075-1079, 2017

111 Niemeyer CM, "Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)" 89 : 3534-3543, 1997

112 Bennett JM, "Changes in the updated 2016 : WHO classification of the myelodysplastic syndromes and related myeloid neoplasms" 16 : 607-609, 2016

113 Pardanani A, "CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia" 27 : 1870-1873, 2013

114 Cazzola M, "Biologic and clinical significance of somatic mutations of SF3B1in myeloid and lymphoid neoplasms" 121 : 260-269, 2013

115 Kurzrock R, "BCR rearrangement-negative chronic myelogenous leukemia revisited" 19 : 2915-2926, 2001

116 Wang SA, "Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms" 123 : 2645-2651, 2014

117 Mughal TI, "An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms" 100 : 1117-1130, 2015

118 Droin N, "Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia" 115 : 78-88, 2010

119 Broséus J, "Age, JAK2(V617F)and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis" 27 : 1826-1831, 2013

120 Gelsi-Boyer V, "ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia" 151 : 365-375, 2010

121 Babushok DV, "A brief, but comprehensive, guide to clonal evolution in aplastic anemia" 2018 : 457-466, 2018

122 Soenen V, "17p deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ" 91 : 1008-1015, 1998